IP Library Granted Patent US 7,805,201
Granted Patent B2
US 7,805,201 · App. 11/111,236 · Granted Sep 28, 2010

Treating a tumor or the like with an electric field

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,805,201
App. No.
11/111,236
Granted
Sep 28, 2010
Kind
B2
Abstract

Cells that are in the late anaphase or telophase stages of cell division are vulnerable to damage by AC electric fields that have specific frequency and field strength characteristics. The selective destruction of rapidly dividing cells can therefore be accomplished by imposing an AC electric field in a target region for extended periods of time. Some of the cells that divide while the field is applied will be damaged, but the cells that do not divide will not be harmed. This selectively damages rapidly dividing cells like tumor cells, but does not harm normal cells that are not dividing. Since the vulnerability of the dividing cells is strongly related to the alignment between the long axis of the dividing cells and the lines of force of the electric field, improved results are obtained when the field is sequentially imposed in different directions.

Claims (28)

1. An apparatus for selectively destroying dividing cells in living tissue, the dividing cells having polarizable or polar intracellular members, the apparatus comprising:

a first electrode having a first surface configured for placement against the living tissue, the first electrode having a first conductor that is electrically insulated from the first surface;

a second electrode having a second surface configured for placement against the living tissue, the second electrode having a second conductor that is electrically insulated from the second surface; and

an alternating voltage source for applying an alternating electric potential across the first and second conductors so that an electric field is produced in the living tissue, wherein passage of the electric field through the dividing cells in late anaphase or telophase transforms the electric field into a non-homogenous electric field that produces an increased density electric field in a region of a cleavage furrow of the dividing cells, and wherein the electric field has amplitude and frequency characteristics such that long-term application of the electric field causes the destruction of cells as they divide, but wherein the electric field is sufficiently small so that during long-term application of the electric field, the destruction of the dividing cells is not caused by heat.

2. The apparatus of claim 1 , wherein the frequency of the electric field is such that the non-homogeneous electric field produced in the dividing cells defines electric field lines which generally converge at a region of the cleavage furrow, thereby defining the increased density electric field, resulting in destruction of the dividing cells as a result of the polarizable intracellular members movement toward the furrow.

3. The apparatus of claim 1 , wherein the first conductor is electrically insulated from the first surface by a dielectric member.

4. The apparatus of claim 3 , wherein the second conductor is electrically insulated from the second surface by a dielectric member.

5. The apparatus of claim 4 , wherein each of the first and second dielectric members comprises a layer of titanium dioxide.

6. The apparatus of claim 4 , wherein each of the first and second dielectric members comprises a dielectric coating having a thickness between about 5 microns to about 50 microns.

7. The apparatus of claim 6 , further including: a thin conducting coating disposed on the dielectric coating for contacting the tissue.

8. The apparatus of claim 1 , wherein the alternating electric potential has a frequency of between about 50 KHz to about 500 KHz.

9. The apparatus of claim 1 , wherein the alternating electric potential has a frequency of between about 100 KHz to about 300 KHz.

10. The apparatus of claim 9 , wherein the voltage waveform is selected so that an electric field intensity in tissue to be treated is between about 0.1 V/cm to about 10 V/cm.

11. The apparatus of claim 9 , wherein the voltage waveform is selected so that an electric field intensity in tissue to be treated is between about 1 V/cm to about 5 V/cm.

12. A method for selectively destroying dividing cells in living tissue, the dividing cells having polarizable intracellular members, the method comprising the steps of:

positioning first and second electrodes in relation to the living tissue, each of the electrodes having a surface configured for placement against the living tissue and a conductor that is electrically insulated from the surface;

applying an alternating electric potential between the first and second conductors so that the living tissue is subjected to an alternating electric field,

wherein passage of the electric field through the dividing cells in late anaphase or telophase transforms the electric field into a non-homogeneous electric field that produces an increased density electric field in a region of a cleavage furrow of the dividing cells, and wherein the electric field has amplitude and frequency characteristics such that long-term application of the electric field causes the destruction of cells as they divide, but wherein the electric field is sufficiently small so that during long-term application of the electric field, the destruction of the dividing cells is not caused by heat.

13. The method of claim 12 , wherein the frequency of the electric field is such that the non-homogeneous electric field produced in the dividing cells defines electric field lines which generally converge at a region of the cleavage furrow, thereby defining the increased density electric field, resulting in destruction of the dividing cells as a result of the polarizable intracellular members movement toward the furrow.

14. The method of claim 12 , wherein positioning the first and second electrodes comprises: positioning the surfaces in contact with the living tissue.

15. The method of claim 12 , wherein positioning the first and second electrodes comprises: positioning the surfaces in contact with the living tissue with a conductive gel disposed between each of the surfaces and the living tissue.

16. The method of claim 12 , wherein the alternating electric field has a frequency between about 50 KHz and about 500 KHz.

17. The method of claim 12 , wherein the alternating electric field has a frequency between about 100 KHz and about 300 KHz.

18. The method of claim 17 , wherein the electric field intensity in the living tissue is between about 1 V/cm to about 5 V/cm.

19. The method of claim 12 , further comprising the step of: rotating the electric field with respect to the living tissue.

20. An apparatus for selectively destroying dividing cells that are in a localized area of living tissue, the dividing cells having polarizable intracellular members, the apparatus comprising:

at least two electrodes, each electrode having an associated conductor and a dielectric material configured for placement against living tissue that insulates the conductor from the living tissue; and

an electric field source for applying an alternating electric potential across the conductors such that a resulting electric field in the dividing cells is transformed into a non-homogenous electric field that produces an increased density electric field in a region of the dividing cells, the non-homogenous electric field being of sufficient intensity to cause the intracellular members to be drawn to the region where the electric field has increased density to cause a pressure increase in this region which causes a structural breakdown of the dividing cells wherein the electric field is sufficiently small such that the structural breakdown of the dividing cells is not caused by heat.

Assignments (15)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825 Recorded Aug 25, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 053597/0335 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398 Recorded Aug 19, 2020
From: BPCR LIMITED PARTNERSHIP
To: NOVOCURE GMBH
Reel/Frame 053538/0623 →
OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT Recorded May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 045278/0825 Recorded Apr 14, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052391/0549 →
RELEASE OF SECURITY INTEREST Recorded Apr 13, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052383/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 050110/0098 →
SECURITY INTEREST Recorded May 6, 2019
From: NOVOCURE GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 050395/0398 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2018
From: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
To: NOVOCURE LIMITED
Reel/Frame 044858/0416 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045278/0825 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045284/0851 →
SECURITY INTEREST Recorded Feb 2, 2015
From: NOVOCURE LIMITED
To: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
Reel/Frame 034866/0402 →
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2013
From: DEUTSCHE BANK TRUST COMPANY AMERICAS
To: NOVOCURE LIMITED
Reel/Frame 031866/0567 →